The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study
Open accessAbstract
Background Rare cancers pose challenges for diagnosis, treatments, and clinical decision making. Information about rare cancers is scant. The RARECARE project defined rare cancers as those with an annual incidence of less than six per 100 000 people in European Union (EU). We updated the estimates of the burden of rare cancers in Europe, their time trends in incidence and survival, and provide information about centralisation of treatments in seven European countries.Methods We analysed data from 94 cancer registries for more than 2 million rare cancer diagnoses, to estimate European incidence and survival in 2000-07 and the corresponding time trends during 1995-2007. Incidence was calculated as the number of new cases divided by the corresponding total person-years in the population. 5-year relative survival was calculated by the Ederer-2 method. Seven registries (Belgium, Bulgaria, Finland, Ireland, the Netherlands, Slovenia, and the Navarra region in Spain) provided additional data for hospitals treating about 220 000 cases diagnosed in 2000-07. We also calculated hospital volume admission as the number of treatments provided by each hospital rare cancer group sharing the same referral pattern.Findings Rare cancers accounted for 24% of all cancers diagnosed in the EU during 2000-07. The overall incidence rose annually by 0.5% (99·8% CI 0·3-0·8). 5-year relative survival for all rare cancers was 48·5% (95% CI 48·4 to 48·6), compared with 63·4% (95% CI 63·3 to 63·4) for all common cancers. 5-year relative survival increased (overall 2·9%, 95% CI 2·7 to 3·2), from 1999-2001 to 2007-09, and for most rare cancers, with the largest increases for haematological tumours and sarcomas. The amount of centralisation of rare cancer treatment varied widely between cancers and between countries. The Netherlands and Slovenia had the highest treatment volumes.Interpretation Our study benefits from the largest pool of population-based registries to estimate incidence and survival of about 200 rare cancers. Incidence trends can be explained by changes in known risk factors, improved diagnosis, and registration problems. Survival could be improved by early diagnosis, new treatments, and improved case management. The centralisation of treatment could be improved in the seven European countries we studied.Funding The European Commission (Chafea).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, translating the capabilities of current patch-based foundation models to address patient- and slide-level clinical challenges still remains complex due to the immense scale of gigapixel WSIs, compounded by the small size of patient cohorts in real-world evidence39–42, especially for rare diseases with limited training data43–45.”
From A multimodal whole-slide foundation model for pathology (2025) · cites this paper as [43]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Classification of Diseases for Oncology
National Cancer Institute (2020) · Definitions · doi:10.32388/1bjeus · Cited by 3,810
Angelis, R. D., Sant, M., Coleman, M. P., Francisci, S., Baili, P., Pierannunzio, D., Trama, A., Visser, O. J., Brenner, H., Ardanáz, E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70546-1 · Cited by 1,888
Self-citationWorldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis
Vaccarella, S., Franceschi, S., Bray, F., Wild, C. P., Plummer, M., & Dal Maso, L. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1604412 · Cited by 1,145
Rare cancers are not so rare: The rare cancer burden in Europe
Gatta, G., van der Zwan, J. M., Casali, P. G., Siesling, S., Tos, A. P. D., Kunkler, I. H., Otter, R., Licitra, L. F., Mallone, S., Tavilla, A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.08.008 · Cited by 813
Self-citationHuman papillomavirus related head and neck cancer survival: A systematic review and meta-analysis
O’Rorke, M. A., Ellison, M. V., Murray, L., Moran, M., James, J. A., & Anderson, L. A. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.06.019 · Cited by 422
Self-citationHeck, J. E., Berthiller, J., Vaccarella, S., Winn, D. M., Smith, E., Shangina, O., Schwartz, S. M., Purdue, M. P., Pilarska, A., Eluf‐Neto, J., et al. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyp350 · Cited by 385
Recent changes in the epidemiology of head and neck cancer
Curado, M. P., & Hashibe, M. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32832a68ca · Cited by 354
Kantarjian, H. M., O'Brien, S. M., Jabbour, E. J., Garcia‐Manero, G., Quintás‐Cardama, A., Shan, J., Rios, M. B., Ravandi, F., Faderl, S. H., Kadia, T. M., et al. (2012) · Blood · doi:10.1182/blood-2011-08-358135 · Cited by 335
Sant, M., Minicozzi, P., Mounier, M., Anderson, L. A., Brenner, H., Holleczek, B., Marcos‐Gragera, R., Maynadié, M., Monnereau, A., Osca‐Gelis, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70282-7 · Cited by 292
Self-citationLepage, C., Capocaccia, R., Hackl, M., Lemmens, V., Molina‐Montes, E., Pierannunzio, D., Sant, M., Trama, A., Faivre, J., Hackl, M., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.034 · Cited by 149
Self-citationOesophageal cancer survival in Europe: A EUROCARE-4 study
Gavin, A., Francisci, S., Foschi, R., Donnelly, D. W., Lemmens, V. E. P. P., Brenner, H., & Anderson, L. A. (2012) · Cancer Epidemiology · doi:10.1016/j.canep.2012.07.009 · Cited by 132
Self-citationRossi, S., Baili, P., Capocaccia, R., Caldora, M., Carrani, E., Minicozzi, P., Pierannunzio, D., Santaquilani, M., Trama, A., Allemani, C., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.001 · Cited by 129
Self-citationTrama, A., Foschi, R., Larrañaga, N., Sant, M., Fuentes‐Raspall, R., Serraino, D., Tavilla, A., Eycken, L. J. V., Nicolai, N., Hackl, M., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.027 · Cited by 113
Self-citationvan Harten, M. C., de Ridder, M., Hamming‐Vrieze, O., Smeele, L. E., Balm, A. J. M., & van den Brekel, M. W. M. (2014) · Oral Oncology · doi:10.1016/j.oraloncology.2013.12.018 · Cited by 103
Impact of Volume and Specialization for Cancer Surgery
Weitz, J., Koch, M., Friess, H., & Büchler, M. W. (2004) · Digestive Surgery · doi:10.1159/000080198 · Cited by 84
Endocrine Tumours: Epidemiology of malignant digestive neuroendocrine tumours
Lepage, C., Bouvier, A., & Faivre, J. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0418 · Cited by 65
Self-citationData Quality in Rare Cancers Registration: The Report of the RARECARE Data Quality Study
Trama, A., Marcos‐Gragera, R., Pérez, M. J. S., van der Zwan, J. M., Ardanáz, E., Bouchardy, C., Rodríguez, J. M. M., Martínez, C., Capocaccia, R., Vicentini, M., et al. (2016) · Tumori Journal · doi:10.5301/tj.5000559 · Cited by 32
Self-citationFunnel plots for population-based cancer survival: principles, methods and applications
Quaresma, M., Coleman, M. P., & Rachet, B. (2013) · Statistics in Medicine · doi:10.1002/sim.5953 · Cited by 28
Manual for coding and reporting haematological malignancies.
(2010) · PubMed · Cited by 20
Information network on Rare Cancers
van der Zwan, J. M., Trama, A., Capocaccia, R., Gatta, G., & Siesling, S. (2014) · University of Twente Research Information · Cited by 9
Self-citationOncologist Perspectives on Rare Cancer Care: A Nationwide Survey
Shin, D. W., Cho, J., Yang, H. K., Kim, S. Y., Lee, S. H., Suh, B., Shin, H., Lee, H. J., Kim, D. G., & Park, J. H. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2014.086 · Cited by 8
Improving methodology to go beyond histology in rare cancers
Casali, P. G. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70089-5 · Cited by 3
Research works printed but not linked: 1
- Ederer, 1961, The relative survival: a statistical methodology, Natl Cancer Inst Monogr, 6, 101
Cited by
Sorted by citations
Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I. P., Bovée, J. V. M. G., Brodowicz, T., Broto, J. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy096 · Cited by 1,615
Towards a general-purpose foundation model for computational pathology
Chen, R. J., Ding, T., Lu, M. Y., Williamson, D. F. K., Jaume, G., Song, A. H., Chen, B., Zhang, A., Shao, D., Shaban, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02857-3 · Cited by 1,560
Gronchi, A., Miah, A. B., Dei Tos, A. P., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.07.006 · Cited by 1,115
Self-citationA visual-language foundation model for computational pathology
Lu, M. Y., Chen, B., Williamson, D. F. K., Chen, R. J., Liang, I., Ding, T., Jaume, G., Odintsov, I., Le, L. P., Gerber, G., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02856-4 · Cited by 966
Machiels, J.-P., Leemans, C. R., Golusiński, W., Grau, C., Licitra, L. F., & Grégoire, V. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.011 · Cited by 945
Metadata
- Authors
- Gatta, G., Capocaccia, R., Botta, L., Mallone, S., De Angelis, R., Ardanaz, E., Comber, H., Dimitrova, N., Leinonen, M. K., Siesling, S., van der Zwan, J. M., Van Eycken, L., Visser, O., Žakelj, M. P., Anderson, L. A., Bella, F., Kaire, I., Otter, R., Stiller, C. A., Trama, A., Hackl, M., Henau, K., Van Damme, N., Valerianova, Z., Sekerija, M., Dušek, L., Mägi, M., Paapsi, K., Malila, N., Velten, M., Troussard, X., Bouvier, V., Guizard, A.-V., Bouvier, A.-M., Arveux, P., Maynadié, M., Woronoff, A.-S., Robaszkiewicz, M., Baldi, I., Monnereau, A., Tretarre, B., Colonna, M., Molinié, F., Bara, S., Schvartz, C., Lapôtre-Ledoux, B., Grosclaude, P., Stabenow, R., Luttmann, S., Nennecke, A., Engel, J., SchubertFritschle, G., Heidrich, J., Holleczek, B., Jónasson, J. G., Clough-Gorr, K., Mazzoleni, G., Giacomin, A., Sardo, A. S., Barchielli, A., Serraino, D., Collarile, P., Pannozzo, F., Ricci, P., Autelitano, M., Spagnoli, G., Fusco, M., Usala, M., Vitale, F., Michiara, M., Tumino, R., Mangone, L., Falcini, F., Ferretti, S., Filiberti, R. A., Marani, E., Caiazzo, A. L., Iannelli, A., Sensi, F., Piffer, S., Gentilini, M., Madeddu, A., Colanino, A. Z., Maspero, S., Candela, P., Stracci, F., Tagliabue, G., Rugge, M., Baili, P., Minicozzi, P., Sant, M., Tereanu, C., Francisci, S., Tavilla, A., Pierannunzio, D., Rossi, S., Santaquilani, M., Knijn, A., Pildava, S., Smailyte, G., Calleja, N., Agius, D., Johannesen, T. B., Rachtan, J., Gózdz, S., Blaszczyk, J., Kepska, K., Lacerda, G. F. D., Bento, M. J., Miranda, A., Diba, C. S., Žagar, T., Almar, E., Larrañaga, N., Munain, A. L. D., Torrella-Ramos, A., García, J. M. D., Marcos-Gragera, R., Sanchez, M. J., Navarro, C., Salmeron, D., Moreno-Iribas, C., Galceran, J., Carulla, M., Mousavi, M., Bouchardy, C., Ess, S. M., Bordoni, A., Konzelmann, I., Rashbass, J., Gavin, A., Brewster, D. H., Huws, D. W., Ho, V. K., & Benhamou, E.
- Affiliations
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Istituto Superiore di Sanità (IT)
- National Cancer Registry (IE)
- Finnish Cancer Registry (FI)
- Netherlands Comprehensive Cancer Organisation (NL)
- Institute of Oncology Ljubljana (SI)
- Queen's University Belfast (GB)
- Policlinico Universitario di Catania (IT)
- Institut Scientifique de Santé Publique (BE)
- Public Health England (GB)
- Instituto de Salud Pública de Navarra (ES)
- Corresponding author
- Gatta, Gemma
- ORCID
- Gatta, Gemma
- Capocaccia, Riccardo
- Botta, Laura
- Mallone, Sandra
- Comber, Harry
- Dimitrova, Nadya
- Leinonen, Maarit K
- Siesling, Sabine
- Visser, Otto
- Anderson, Lesley A
- Stiller, Charles A
- Trama, Annalisa
- Dušek, Ladislav
- Mägi, Margit
- Paapsi, Keiu
- Malila, Nea
- Troussard, Xavier
- Guizard, Anne-Valérie
- Bouvier, Anne-Marie
- Arveux, Patrick
- Maynadié, Marc
- Woronoff, Anne-Sophie
- Robaszkiewicz, Michel
- Baldi, Isabelle
- Monnereau, Alain
- Colonna, Marc
- Molinié, Florence
- Grosclaude, Pascale
- Luttmann, Sabine
- Nennecke, Alice
- Mazzoleni, Guido
- Serraino, Diego
- Vitale, Francesco
- Tumino, Rosario
- Falcini, Fabio
- Ferretti, Stefano
- Filiberti, Rosa Angela
- Piffer, Silvano
- Tagliabue, Giovanna
- Rugge, Massimo
- Baili, Paolo
- Minicozzi, Pamela
- Sant, Milena
- Francisci, Silvia
- Tavilla, Andrea
- Pierannunzio, Daniela
- Rossi, Silvia
- Santaquilani, Mariano
- Knijn, Arnold
- Pildava, Santa
- Calleja, Neville
- Rachtan, Jadwiga
- Miranda, Ana
- Žagar, Tina
- Almar, Enrique
- Larrañaga, Nerea
- García, José María Díaz
- Navarro, Carmen
- Bouchardy, Christine
- Ess, Silvia M.
- Gavin, Anna
- Brewster, David H
- Huws, Dyfed Wyn
- Ho, Vincent KY
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 18
- Issue
- 8
- Pages
- 1022-1039
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2729284305
- Cited by
- 516
- References
- 22
- Citations by year
- 2026: 60 · 2025: 82 · 2024: 81 · 2023: 71 · 2022: 64 · 2021: 52 · 2020: 47 · 2019: 27 · 2018: 24 · 2017: 6
- FWCI
- 12.46
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-08-01)
- Open access
- bronze
- doi.org
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- OAR@UM (University of Malta) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion, other-oa)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, cc-by)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- European Commission through the Consumers, Health, Agriculture and Food Executive Agency (Grant No. 2000111201)
- Topics
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advances in Oncology and Radiotherapy
- Health Sciences › Medicine › Oncology › COVID-19 and healthcare impacts
- Keywords
- rare tumor, cancer incidence, cancer survival, cancer registry, incidence trends, sarcoma, Europe, referral patterns, healthcare resource allocation, cancer care costs
- MeSH terms
- Cancer Care Facilities, Delivery of Health Care, Europe, Female, Hospitalization, Humans, Male, Neoplasms, Registries, Incidence, Survival Rate, Rare Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
